{"id":44006,"date":"2022-05-17T16:01:12","date_gmt":"2022-05-17T14:01:12","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\/"},"modified":"2022-05-17T16:01:12","modified_gmt":"2022-05-17T14:01:12","slug":"enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\/","title":{"rendered":"Enlyte Names Steve Laudermilch EVP of Mitchell Casualty Solutions Group"},"content":{"rendered":"
\n

\nP&C executive will head company\u2019s auto casualty and workers\u2019 comp technology division<\/i>\n<\/p>\n

SAN DIEGO–(BUSINESS WIRE)–Enlyte<\/a>, the parent brand of Mitchell, Genex and Coventry, has announced today that Steve Laudermilch has joined the company to serve as executive vice president and general manager of Mitchell\u2019s casualty solutions group (CSG).\n<\/p>\n

<\/a><\/p>\n

\nWith 25 years of senior leadership experience in workers\u2019 compensation and auto casualty claims, Laudermilch will be charged with leading Mitchell\u2019s CSG, bringing cutting-edge claims technology and workflow connectivity solutions to the auto casualty and workers\u2019 comp markets, while helping restore the lives of injured drivers and employees.\n<\/p>\n

\n\u201cWe\u2019re very excited and honored to have Steve Laudermilch join the Enlyte team,\u201d said Alex Sun, Enlyte CEO. \u201cSteve is a proven leader who comes to us with a successful track record of delivering results in workers\u2019 compensation and auto casualty for global claims organizations. We look forward to him utilizing his extensive experience and knowledge to propel our products and services for years to come.\u201d\n<\/p>\n

\nPrior to joining Enlyte, Laudermilch served as U.S. chief claims officer with Argo Group, a major underwriter of specialty insurance products in the property and casualty market. In this role, he led the technical claims teams for casualty, workers\u2019 comp, financial lines, property and programs, and had oversight for claims operations and shared services. Prior to Argo, Laudermilch held key positions at Chubb, a leading property and casualty insurance company, and Deloitte Consulting.\n<\/p>\n

\nLaudermilch holds an MBA from Saint Joseph\u2019s University, Philadelphia, and a BA in economics from Ursinus College, Collegeville, PA.\n<\/p>\n

\nAbout Enlyte<\/b>\n<\/p>\n

\nEnlyte <\/b>(www.enlyte.com<\/a>) is the parent brand of Mitchell | Genex | Coventry, a leader in cost – containment technology, independent medical exams (IME), provider and specialty networks, case management services, pharmacy benefit and disability management. The three businesses have recently aligned their joint industry expertise and advanced technology solutions into a combined organization of nearly 6,000 associates committed to simplifying and optimizing property, casualty and disability claims processes and services.\n<\/p>\n

\nAbout Mitchell<\/b>\n<\/p>\n

\nMitchell International<\/b> (www.mitchell.com<\/a>) delivers smart technology solutions and services to the auto insurance, collision repair, disability and workers\u2019 compensation markets. Through deep industry expertise, connections throughout the insurance ecosystem and advanced technology such as artificial intelligence and cloud-based solutions, Mitchell enables its customers and clients to succeed in today\u2019s ever-changing environment. Each month, Mitchell processes tens of millions of transactions for more than 300 insurance providers, 20,000 collision repair facilities and 70,000 pharmacies. Its comprehensive solution and service portfolio empowers clients to restore lives after a challenging event.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nTom Kerr
\n
610-964-5213
\n
tom.kerr@enlyte.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

P&C executive will head company\u2019s auto casualty and workers\u2019 comp technology division SAN DIEGO–(BUSINESS WIRE)–Enlyte, the parent brand of Mitchell, Genex and Coventry, has announced today that Steve Laudermilch has joined the company to serve as executive vice president and general manager of Mitchell\u2019s casualty solutions group (CSG). With 25 years of senior leadership experience … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44006","6":"format-standard","7":"category-industry"},"yoast_head":"\nEnlyte Names Steve Laudermilch EVP of Mitchell Casualty Solutions Group - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enlyte Names Steve Laudermilch EVP of Mitchell Casualty Solutions Group - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"P&C executive will head company\u2019s auto casualty and workers\u2019 comp technology division SAN DIEGO–(BUSINESS WIRE)–Enlyte, the parent brand of Mitchell, Genex and Coventry, has announced today that Steve Laudermilch has joined the company to serve as executive vice president and general manager of Mitchell\u2019s casualty solutions group (CSG). With 25 years of senior leadership experience ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-17T14:01:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220517005051\/en\/1455388\/21\/Enlyte_color_logo%402x_0.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Enlyte Names Steve Laudermilch EVP of Mitchell Casualty Solutions Group\",\"datePublished\":\"2022-05-17T14:01:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\\\/\"},\"wordCount\":443,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220517005051\\\/en\\\/1455388\\\/21\\\/Enlyte_color_logo%402x_0.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\\\/\",\"name\":\"Enlyte Names Steve Laudermilch EVP of Mitchell Casualty Solutions Group - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220517005051\\\/en\\\/1455388\\\/21\\\/Enlyte_color_logo%402x_0.jpg\",\"datePublished\":\"2022-05-17T14:01:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220517005051\\\/en\\\/1455388\\\/21\\\/Enlyte_color_logo%402x_0.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220517005051\\\/en\\\/1455388\\\/21\\\/Enlyte_color_logo%402x_0.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enlyte Names Steve Laudermilch EVP of Mitchell Casualty Solutions Group\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enlyte Names Steve Laudermilch EVP of Mitchell Casualty Solutions Group - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\/","og_locale":"en_US","og_type":"article","og_title":"Enlyte Names Steve Laudermilch EVP of Mitchell Casualty Solutions Group - Pharma Trend","og_description":"P&C executive will head company\u2019s auto casualty and workers\u2019 comp technology division SAN DIEGO–(BUSINESS WIRE)–Enlyte, the parent brand of Mitchell, Genex and Coventry, has announced today that Steve Laudermilch has joined the company to serve as executive vice president and general manager of Mitchell\u2019s casualty solutions group (CSG). With 25 years of senior leadership experience ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-17T14:01:12+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220517005051\/en\/1455388\/21\/Enlyte_color_logo%402x_0.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Enlyte Names Steve Laudermilch EVP of Mitchell Casualty Solutions Group","datePublished":"2022-05-17T14:01:12+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\/"},"wordCount":443,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220517005051\/en\/1455388\/21\/Enlyte_color_logo%402x_0.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\/","url":"https:\/\/pharma-trend.com\/en\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\/","name":"Enlyte Names Steve Laudermilch EVP of Mitchell Casualty Solutions Group - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220517005051\/en\/1455388\/21\/Enlyte_color_logo%402x_0.jpg","datePublished":"2022-05-17T14:01:12+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220517005051\/en\/1455388\/21\/Enlyte_color_logo%402x_0.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220517005051\/en\/1455388\/21\/Enlyte_color_logo%402x_0.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/enlyte-names-steve-laudermilch-evp-of-mitchell-casualty-solutions-group\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Enlyte Names Steve Laudermilch EVP of Mitchell Casualty Solutions Group"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44006","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44006"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44006\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44006"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44006"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44006"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}